MindRank Announces U.S. FDA Clearance of IND Application for MDR-001, a Novel GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity
SHANGHAI and HANGZHOU, China, Dec. 26, 2022 /PRNewswire/ -- MindRank, an artificial intelligence (AI)-empowered drug discovery company, announces today that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MDR-001, an oral small-molecule glucagon-like peptide 1 receptor agonist (GLP-1 RA), for the treatment of obesity and type 2 diabetes mellitus (T2DM),...
CJ CheilJedang, and Emmyon, Inc. sign a Licensing Agreement to commercialize a dietary supplement with natural extracts for use in significant improvement of skeletal muscle mass and function in...
SEOUL, South Korea and ROCHESTER, Minn., Dec. 26, 2022 /PRNewswire/ -- CJ Food and Nutrition Tech (CJ FNT), a newly formed business unit of CJ CheilJedang, a South Korea based global food and nutrition company, and Emmyon, Inc., a privately-held biotechnology start-up company based in Rochester, MN USA, have signed an exclusive licensing agreement establishing a strategic partnership between...
In Vitro Fertilization Services Industry to be Boosted by Innovative Technologies
Global IVF services market is expected to reach $43.97 billion by 2027, registering growth at a CAGR of 20.46% SAN ANTONIO, Dec. 26, 2022 /PRNewswire/ -- In vitro fertilization (IVF), one type of assisted reproductive technology (ART), is becoming more popular due to an increase in infertility rates worldwide, according to Frost & Sullivan's recent analysis on the...
China actively optimizes COVID-19 response measures to better prepare for challenges
BEIJING, Dec. 26, 2022 /PRNewswire/ -- As multiple regions in China have seen surging COVID-19 infections, local governments are taking swift and precise measures to prevent severe cases, protect people's health, and build a barrier against the epidemic. These measures include providing timely medical treatment, meeting medicine needs, improving health services for the elderly and other key groups, promoting...
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company’s Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 26, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19 vaccine ReCOV in the Philippines. This clinical study aims to...
Pulnovo Medical will be attending JPM Healthcare Conference 2023
SHANGHAI, Dec. 24, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM innovative platform, will be attending the upcoming 41st J.P. Morgan Healthcare Conference 2023 to discuss the latest trends in innovative technologies and development strategies in the medical device sector with global peers. This will be the first time that Pulnovo will be participating in the J.P....
AAHRPP Accredits Three More Research Organizations, Including First Hospital in Japan
Twelve earn accreditation in 2022, returning to pre-COVID-19 levels WASHINGTON, Dec. 23, 2022 /PRNewswire/ -- The Association for the Accreditation of Human Research Protection Programs has accredited three more research organizations, including the first hospital in Japan, the flagship university of New Jersey and a consortium of over 150 U.S. colleges and...
Hyphens Pharma licenses Winlevi® for all 10 ASEAN countries from Cosmo Pharmaceuticals
Winlevi® is a first-in-class topical drug for the treatment of acne approved by U.S. FDA in August 2020. It will reinforce our Proprietary Brand segment's dermatological franchise. SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare...
PVmed Raises US $14 Million Series A Funding from Cherami, Philips, JHF, COCOCAPITAL, and Strategy Capital
Will Support Rapid Expansion of PVmed's AI Cancer Treatment Product Portfolio GUANGZHOU, China, Dec. 23, 2022 /PRNewswire/ -- Perception Vision Medical Technologies Co., Ltd. (PVmed), a global artificial intelligence (AI) cancer treatment company, headquartered in Guangzhou, China, has secured US $14 million (RM 100 million) in Series A funding from investors including Cherami Investment Group, Philips, JHF Investment,...
JUNIPER BIOLOGICS WINS M&A AWARD 2022 BY ACQUISITION INTERNATIONAL
Best Cell & Gene Therapy Acquisition 2022: Juniper Biologics/Kolon Life Science SINGAPORE, Dec. 23, 2022 /PRNewswire/ -- Singapore-headquartered Juniper Biologics Pte Ltd, a science-led healthcare company focused on commercialising novel therapies, was awarded Acquisition International's M&A Award 2022 for the category of Best Cell & Gene Therapy Acquisition 2022. Acquisition international hosted the M&A awards for the sixth year,...
